Cambridge Research & Instrumentation (CRi) and VisEn Medical have signed a non-exclusive agreement to enable CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America.
The distribution partnership is designed to extend their fluorescence imaging technologies, applications and standards in research and drug development, according to the Bedford, Mass.-based Cri and the Woburn, Mass.-based VisEn.
The companies said that VisEn's imaging agents and labels are designed to provide biologically-specific imaging readouts. VisEn offers more than 25 different fluorescence molecular agents for imaging disease-associated biologic targets, processes and pathways, with new agents expected for launch in 2009. Research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease and pulmonary diseases, all in the context of the living animal.
VisEn said it also offers agent labeling platforms, including its VivoTag fluorescence labeling dyes for agent development, and its NanoSpark labeling nanoparticles. VisEn's agents and labels are designed to be compatible with fluorescence imaging systems, including the CRi Maestro system with its multispectral imaging technology. With a focus on translational research and results, VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.